New Delhi: The Indian pharmaceutical market (IPM) has returned to negative volume growth this Q3FY25 after two consecutive quarters of modest positive growth, according to Goldman Sachs report.However, strong pricing growth (+5.3 per cent YoY) and the launch of new products from




